RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients

BACKGROUND: Adjuvant chemotherapy is a major adjuvant treatment modality for hormonal receptor (HR)-positive and HER2-negative early breast cancer, but only 2%-20% of patients derive practical benefits. How to balance its potential benefits and risks becomes a challenging clinical problem. The purpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haibo, Ma, Li, Zhang, Yanan, Wang, Ouchen, Wei, Zhimin, Xie, Xiaohong, Zha, Xiaoming, Zeng, Jian, Lv, Qing, Ren, Yu, Wang, Huimin, Du, Furong, Cao, Shangzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769189/
https://www.ncbi.nlm.nih.gov/pubmed/36568204
http://dx.doi.org/10.3389/fonc.2022.896431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769189/
https://www.ncbi.nlm.nih.gov/pubmed/36568204
http://dx.doi.org/10.3389/fonc.2022.896431

Ejemplares similares